News & Updates

THE EUROPEAN SOCIETY OF MEDICINE

Amyotrophic Lateral Sclerosis is a spectrum of diseases that needs a broad treatment approach Siobhan P Ellison DVM PhD1

Clinical Trial FC-US-001

June 21, 2024 The last subjects for the clinical trial using FC-12738, affectionally called TVALA, had their final follow up visit on ...

Richard H Helms 1949-2024

In hindsight, Richard Helms remembered he had a non-painful limp in 2018. After multiple consults he was introduced to ALS, that was in...

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study...

MOLECULAR MECHANISMS OF REDOX REGULATION IN INFLAMMATION

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first...

TVALA Fortune Journal

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

NDR starts clinical trial with TVALA

Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS....

NDR publishes novel study

The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R...

Congratulations to Dr. Susanne Petri and her team!

NDR would like to congratulate Dr. Susanne Petri and her research team on their recent paper Altered Immunomodulatory Responses in the...

NDR awards Dr. Chandler Walker $1.1 Million for ALS Research

Dr. Chandler Walker, associate professor in the Department of Biomedical Sciences and Comprehensive Care at Indiana University School of ...

Ghada Maged receives NDR student award

NDR is pleased to announce research support for Ghada Maged for an ALS biomarkers project. Ms. Maged is currently completing an M. Sc....

A Personal Message from Dr. Siddique

In this final installment, Dr. Siddique delivers a personal message.

Second Video Installment

In this second installment, Dr. Siddique discusses the future of ALS research and its implications for researchers and patients. We hope...

New Video Series

We're pleased to announce that Northwestern University-Feinberg School of Medicine has produced a three-part video series on ALS,...

NDR's TVALA® Trademarked

The lead molecule under development by NDR for treating neuroinflammation is the retro-inverso thymopentin, TVALA®. The application for...

Sayuri Miyamoto to present a poster at the Paris Redox 2022 World Conference

NDR is pleased to congratulate Dr. Sayuri Miyamoto and her co-workers Adriano Chaves-Filho, Rosangela Santos, Rodrigo Lima, Larissa...

Dr. Susanne Petri Joins NDR Scientific Group

NDR Inc is pleased to announce that Dr. Susanne Petri has joined our scientific group. Dr. Petri is an Associate Professor in the...

NDR awards $1.54 M drug development contract to WuXi App Tec

New drug development

Student Grant Awarded to Rodrigo Santiago Lima

Student grants in ALS